Specialty pharmaceutical-company United Therapeutics (UTHR 1.05%) was an outlier stock in the best way on Wednesday. After reporting quarterly figures showing revenue growth in all of its products, the shares closed the day over 14% higher.
United Therapeutics took in $446.5 million in revenue for its Q2, which was a very healthy 23% higher year over year. Net income also rose handsomely: On a non-GAAP (adjusted) basis, it advanced by 19% to land at $193.5 million, or $4.09 per share.
Both results trounced analyst estimates. On average, prognosticators tracking the pharmaceutical stock were expecting merely $378.8 million on the top line and $3.02 in adjusted, per-share net profit.
As mentioned, all of the company's products saw gains across that one-year stretch. Revenue for its foundational drug, pulmonary arterial hypertension (PAH) treatment Remodulin, saw a 17% gain to almost $140 million during the quarter, while Remodulin's peer Tyvaso eclipsed that by shooting nearly 29% higher (to just under $154 million). Pediatric neuroblastoma drug Unituxin nearly doubled its revenue to $53 million.
While United Therapeutics didn't proffer any guidance in its earnings release, it indicated that the upward momentum of at least some of those drugs should continue.
The company quoted COO Michael Benkowitz as saying that "we are currently seeing some of the highest levels of referrals of Tyvaso and Orenitram [another PAH treatment] since their launches and we're well on our way to our goal of doubling the number of Tyvaso patients on therapy by the end of 2022."